These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 22089354)
21. Psoriasis, hepatitis B, and the tumor necrosis factor-alpha inhibitory agents: a review and recommendations for management. Abramson A; Menter A; Perrillo R J Am Acad Dermatol; 2012 Dec; 67(6):1349-61. PubMed ID: 22727462 [TBL] [Abstract][Full Text] [Related]
22. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Carroll MB; Bond MI Semin Arthritis Rheum; 2008 Dec; 38(3):208-17. PubMed ID: 18221983 [TBL] [Abstract][Full Text] [Related]
23. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients. Watanabe M; Shibuya A; Takada J; Tanaka Y; Okuwaki Y; Minamino T; Hidaka H; Nakazawa T; Koizumi W Eur J Intern Med; 2010 Aug; 21(4):333-7. PubMed ID: 20603047 [TBL] [Abstract][Full Text] [Related]
24. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Vassilopoulos D; Apostolopoulou A; Hadziyannis E; Papatheodoridis GV; Manolakopoulos S; Koskinas J; Manesis EK; Archimandritis AI Ann Rheum Dis; 2010 Jul; 69(7):1352-5. PubMed ID: 20472596 [TBL] [Abstract][Full Text] [Related]
25. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Mindikoglu AL; Regev A; Schiff ER Clin Gastroenterol Hepatol; 2006 Sep; 4(9):1076-81. PubMed ID: 16861051 [TBL] [Abstract][Full Text] [Related]
26. Low levels of awareness, vaccine coverage, and the need for boosters among health care workers in tertiary care hospitals in India. Sukriti ; Pati NT; Sethi A; Agrawal K; Agrawal K; Kumar GT; Kumar M; Kaanan AT; Sarin SK J Gastroenterol Hepatol; 2008 Nov; 23(11):1710-5. PubMed ID: 18761556 [TBL] [Abstract][Full Text] [Related]
27. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group. Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494 [TBL] [Abstract][Full Text] [Related]
28. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Nordgaard-Lassen I; Dahlerup JF; Belard E; Gerstoft J; Kjeldsen J; Kragballe K; Ravn P; Sørensen IJ; Theede K; Tjellesen L; Dan Med J; 2012 Jul; 59(7):C4480. PubMed ID: 22759856 [TBL] [Abstract][Full Text] [Related]
29. Dermatologists' adherence to the guideline of the Dutch Society of Dermatology and Venereology with respect to the treatment with methotrexate for severe chronic plaque psoriasis: results from a Dutch survey. Berends MA; de Jong EM; van de Kerkhof PC; Gerritsen MJ Dermatology; 2007; 215(1):45-52. PubMed ID: 17587839 [TBL] [Abstract][Full Text] [Related]
30. Public awareness of hepatitis B infection in Turkey as a model of universal effectiveness in health care policy. Gürakar M; Malik M; Keskin O; Idilman R Turk J Gastroenterol; 2014 Jun; 25(3):304-8. PubMed ID: 25141320 [TBL] [Abstract][Full Text] [Related]
31. Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases. Kim YJ; Bae SC; Sung YK; Kim TH; Jun JB; Yoo DH; Kim TY; Sohn JH; Lee HS J Rheumatol; 2010 Feb; 37(2):346-50. PubMed ID: 20008922 [TBL] [Abstract][Full Text] [Related]
32. Hepatitis B reactivation in cancer patients: role of prechemotherapy screening and antiviral prophylaxis. Kawsar HI; Shahnewaz J; Gopalakrishna KV; Spiro TP; Daw HA Clin Adv Hematol Oncol; 2012 Jun; 10(6):370-8. PubMed ID: 22895238 [TBL] [Abstract][Full Text] [Related]
33. Hepatitis B virus reactivation following immunosuppressive therapy: guidelines for prevention and management. Lubel JS; Testro AG; Angus PW Intern Med J; 2007 Oct; 37(10):705-12. PubMed ID: 17894766 [TBL] [Abstract][Full Text] [Related]
34. Oncologists and hepatitis B: a survey to determine current level of awareness and practice of antiviral prophylaxis to prevent reactivation. Khokhar OS; Farhadi A; McGrail L; Lewis JH Chemotherapy; 2009; 55(2):69-75. PubMed ID: 19077421 [TBL] [Abstract][Full Text] [Related]
35. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Esteve M; Saro C; González-Huix F; Suarez F; Forné M; Viver JM Gut; 2004 Sep; 53(9):1363-5. PubMed ID: 15306601 [TBL] [Abstract][Full Text] [Related]
36. Dermatologists' knowledge of and preferences regarding topical steroids. Sandoval LF; Davis SA; Feldman SR J Drugs Dermatol; 2013 Jul; 12(7):786-9. PubMed ID: 23884491 [TBL] [Abstract][Full Text] [Related]
37. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. Yeo W; Chan PK; Ho WM; Zee B; Lam KC; Lei KI; Chan AT; Mok TS; Lee JJ; Leung TW; Zhong S; Johnson PJ J Clin Oncol; 2004 Mar; 22(5):927-34. PubMed ID: 14990649 [TBL] [Abstract][Full Text] [Related]
38. A comparison of current practice patterns of US dermatologists versus published guidelines for the biopsy, initial management, and follow up of patients with primary cutaneous melanoma. Farberg AS; Rigel DS J Am Acad Dermatol; 2016 Dec; 75(6):1193-1197.e1. PubMed ID: 27742167 [TBL] [Abstract][Full Text] [Related]
39. Screening for hepatitis B, C and non-alcoholic fatty liver disease: a survey of community-based physicians. Kallman JB; Arsalla A; Park V; Dhungel S; Bhatia P; Haddad D; Wheeler A; Younossi ZM Aliment Pharmacol Ther; 2009 May; 29(9):1019-24. PubMed ID: 19220207 [TBL] [Abstract][Full Text] [Related]